BSE:500674

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India. More Details


Snowflake Analysis

Flawless balance sheet with proven track record.


Similar Companies

Share Price & News

How has Sanofi India's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 500674 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.2%

500674

0.5%

IN Pharmaceuticals

1.6%

IN Market


1 Year Return

37.0%

500674

49.0%

IN Pharmaceuticals

2.4%

IN Market

Return vs Industry: 500674 underperformed the Indian Pharmaceuticals industry which returned 50.1% over the past year.

Return vs Market: 500674 exceeded the Indian Market which returned 2.3% over the past year.


Shareholder returns

500674IndustryMarket
7 Day-1.2%0.5%1.6%
30 Day1.8%-0.4%4.2%
90 Day10.2%12.5%7.3%
1 Year43.1%37.0%50.9%49.0%4.2%2.4%
3 Year118.0%103.5%28.1%24.6%-1.5%-6.2%
5 Year109.5%89.7%0.6%-3.0%40.4%30.0%

Price Volatility Vs. Market

How volatile is Sanofi India's share price compared to the market and industry in the last 5 years?


Simply Wall St News

2 years ago | Simply Wall St

Best Growth Stock in July

2 years ago | Simply Wall St

Value-Adding Stocks To Buy Now

Valuation

Is Sanofi India undervalued compared to its fair value and its price relative to the market?

43.92x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 500674 (₹8497.85) is trading above our estimate of fair value (₹3968.45)

Significantly Below Fair Value: 500674 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 500674 is poor value based on its PE Ratio (43.9x) compared to the IN Pharmaceuticals industry average (22.8x).

PE vs Market: 500674 is poor value based on its PE Ratio (43.9x) compared to the Indian market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 500674's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 500674 is overvalued based on its PB Ratio (7.3x) compared to the IN Pharmaceuticals industry average (2.2x).


Next Steps

Future Growth

How is Sanofi India forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sanofi India has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Sanofi India performed over the past 5 years?

13.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 500674 has high quality earnings.

Growing Profit Margin: 500674's current net profit margins (14.4%) are higher than last year (13.2%).


Past Earnings Growth Analysis

Earnings Trend: 500674's earnings have grown by 13.4% per year over the past 5 years.

Accelerating Growth: 500674's earnings growth over the past year (14.6%) exceeds its 5-year average (13.4% per year).

Earnings vs Industry: 500674 earnings growth over the past year (14.6%) underperformed the Pharmaceuticals industry 14.7%.


Return on Equity

High ROE: 500674's Return on Equity (16.7%) is considered low.


Next Steps

Financial Health

How is Sanofi India's financial position?


Financial Position Analysis

Short Term Liabilities: 500674's short term assets (₹23.4B) exceed its short term liabilities (₹7.1B).

Long Term Liabilities: 500674's short term assets (₹23.4B) exceed its long term liabilities (₹1.1B).


Debt to Equity History and Analysis

Debt Level: 500674 is debt free.

Reducing Debt: 500674 has not had any debt for past 5 years.

Debt Coverage: 500674 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 500674 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Sanofi India current dividend yield, its reliability and sustainability?

1.25%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 500674's dividend (1.25%) is higher than the bottom 25% of dividend payers in the Indian market (0.56%).

High Dividend: 500674's dividend (1.25%) is low compared to the top 25% of dividend payers in the Indian market (2.3%).


Stability and Growth of Payments

Stable Dividend: 500674's dividend payments have been volatile in the past 10 years.

Growing Dividend: 500674's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (54.8%), 500674's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.8yrs

Average management tenure


CEO

Rajaram Narayanan (52 yo)

2.75yrs

Tenure

₹38,400,000

Compensation

Mr. Rajaram Narayanan serves as Managing Director and Whole Time Director at Sanofi India Ltd. since January 01, 2018 and since October 21, 2015 respectively. Mr. Narayanan serves as Director of Sanofi-Syn ...


CEO Compensation Analysis

Compensation vs Market: Rajaram's total compensation ($USD521.28K) is below average for companies of similar size in the Indian market ($USD808.16K).

Compensation vs Earnings: Rajaram's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Rajaram Narayanan
MD & Director2.75yrs₹38.40mno data
Girish Tekchandani
Compliance Officer & Company Secretary3.92yrs₹11.50mno data
Cherian Mathew
Head of Manufacturing Operations and Additional Director & Whole Time Director1.25yrs₹10.70mno data
Vaibhav Karandikar
Chief Financial Officerno datano datano data
M. Narayanaswamy
Senior Director of Accounting & Taxation36.67yrsno datano data
J. Cama
Senior Director of Legal Affairs & Legal Affairs - South Asia13.58yrs₹7.80mno data
Gaurav Bahadur
Senior Director of Human Resources - India & South Asia7.5yrsno datano data
Goel Devendrakumar
Head of Sri Lanka Operationsno datano datano data
Sanjay Chavan
Head of Country Procurement - India6.75yrsno datano data
Madhusudan Rao
Senior Director of Industrial Affairs - Indiano data₹7.62mno data
Bhatnagar Tarun
Senior Resident Directorno datano datano data
Lalit Wadhawan
Senior Director of Portfolio Management - Nutraceutical Buno datano datano data

6.8yrs

Average Tenure

65yo

Average Age

Experienced Management: 500674's management team is seasoned and experienced (6.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Rajaram Narayanan
MD & Director2.75yrs₹38.40mno data
Cherian Mathew
Head of Manufacturing Operations and Additional Director & Whole Time Director1.25yrs₹10.70mno data
Usha Thorat
Independent Non-Executive Director4.5yrs₹1.85mno data
Rahul Bhatnagar
Independent Director0.25yrno datano data
Aditya Narayan
Independent Non-Executive Chairman4.5yrs₹2.23mno data
Cyril Grandchamp-Desraux
Non-Executive Director3.67yrsno datano data
Charles Alexis Billard
Non-Executive Director2.25yrs₹18.90mno data
Marc-Antoine Lucchini
Non-Executive Director0.25yrno datano data

3.0yrs

Average Tenure

55yo

Average Age

Experienced Board: 500674's board of directors are not considered experienced ( 3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sanofi India Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sanofi India Limited
  • Ticker: 500674
  • Exchange: BSE
  • Founded: 1956
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹192.419b
  • Shares outstanding: 23.03m
  • Website: https://www.sanofiindialtd.com

Number of Employees


Location

  • Sanofi India Limited
  • Sanofi House
  • CTS No. 117-B, L&T Business Park
  • Mumbai
  • Maharashtra
  • 400072
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
500674BSE (Mumbai Stock Exchange)YesEquity SharesININRSep 1998
SANOFINSEI (National Stock Exchange of India)YesEquity SharesININRSep 1998

Biography

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India. It provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, centr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 12:47
End of Day Share Price2020/10/22 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.